Search
Our study provides evidence for geographic clustering of tuberculosis/human immunodeficiency virus co-infection in Ethiopia
Reductions in pneumonia-coded hospital admissions in unvaccinated children predominated in non-Aboriginal children with low incidence of pneumonia
RV1 and RV5 were both effective in preventing laboratory confirmed and notified rotavirus infections among children aged <5 years
We have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
This study provides a quantitative estimate of the total burden of invasive pneumococcal disease preventable by vaccination programs in Australia
The aim of this study was to describe the characteristics of patients with multidrug-resistant tuberculosis and to investigate risk factors
Given the beneficial effect of infant rotavirus vaccination efforts should be taken to optimize rotavirus vaccine coverage in those at highest risk
Influenza infection in young children has a significant impact on medication use, absenteeism and the use of health care service
Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.
COVID-19 is a new multi-organ disease causing considerable worldwide morbidity and mortality. While many recognized pathophysiological mechanisms are involved, their exact causal relationships remain opaque. Better understanding is needed for predicting their progression, targeting therapeutic approaches, and improving patient outcomes. While many mathematical causal models describe COVID-19 epidemiology, none have described its pathophysiology.